DXN Past Earnings Performance
Past criteria checks 0/6
DXN has been growing earnings at an average annual rate of 10%, while the IT industry saw earnings growing at 27.4% annually. Revenues have been growing at an average rate of 18.3% per year.
Key information
10.0%
Earnings growth rate
54.1%
EPS growth rate
| IT Industry Growth | 12.9% |
| Revenue growth rate | 18.3% |
| Return on equity | n/a |
| Net Margin | -21.4% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How DXN makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 11 | -2 | 5 | 0 |
| 31 Mar 24 | 9 | -5 | 5 | 0 |
| 31 Dec 23 | 6 | -8 | 4 | 0 |
| 30 Sep 23 | 5 | -9 | 5 | 0 |
| 30 Jun 23 | 7 | -10 | 5 | 0 |
| 31 Mar 23 | 9 | -8 | 6 | 0 |
| 31 Dec 22 | 12 | -7 | 6 | 0 |
| 30 Sep 22 | 13 | -7 | 6 | 0 |
| 30 Jun 22 | 14 | -7 | 6 | 1 |
| 31 Mar 22 | 12 | -6 | 6 | 1 |
| 31 Dec 21 | 10 | -4 | 5 | 1 |
| 30 Sep 21 | 9 | -5 | 5 | 0 |
| 30 Jun 21 | 8 | -5 | 5 | 0 |
| 31 Mar 21 | 7 | -7 | 6 | 0 |
| 31 Dec 20 | 7 | -9 | 6 | 0 |
| 30 Sep 20 | 6 | -11 | 7 | 0 |
| 30 Jun 20 | 5 | -13 | 8 | 0 |
| 31 Mar 20 | 4 | -12 | 8 | 0 |
| 31 Dec 19 | 3 | -11 | 8 | 0 |
| 30 Sep 19 | 2 | -9 | 8 | 0 |
| 30 Jun 19 | 1 | -7 | 8 | 0 |
| 31 Dec 18 | 3 | -8 | 8 | 0 |
| 30 Jun 18 | 2 | -6 | 4 | 0 |
| 30 Nov 17 | 0 | -2 | 2 | 0 |
Quality Earnings: DXN is currently unprofitable.
Growing Profit Margin: DXN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DXN is unprofitable, but has reduced losses over the past 5 years at a rate of 10% per year.
Accelerating Growth: Unable to compare DXN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DXN is unprofitable, making it difficult to compare its past year earnings growth to the IT industry (7%).
Return on Equity
High ROE: DXN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.